LYCOS RETRIEVER 
Organon: Akzo Nobel
built 623 days ago
Organon is one of the business units of Akzo Nobel. Headquartered in The Netherlands, Akzo Nobel N.V. (NASDAQ: AKZOY) is a market-driven and technology-based company, serving customers throughout the world with health care products, coating and chemicals. Consolidated sales for 2002 totaled $15.05 billion (EUR 14 billion). The company currently employs over 68,000 people in more than 80 countries.
Source:
Organon is the largest of three pharmaceutical business units of Akzo Nobel, a leading global company in pharmaceuticals, coatings, and chemicals. Tags: Team, Virtual Team, Pharmaceutical Company, Microsoft Corp., Intranet, Organon, Team Management, Management Case studies
Source:
As leading pharmaceutical company and as part of Akzo Nobel, Organon introduces its new logo in very close cooperation with RGN. Organon rightfully calls itself the largest innovative biopharmaceutical company from Dutch grounds. With its new logo, Organon can emphasize that the power of innovation reigns the whole organisation. The new logo, which is the heart of Organon's new identity, is closely connected to the decision to divide the pharmaceutical activities of its mother company Akzo Nobel.
Source:
Organon – with shared head offices in Roseland, NJ, USA and Oss, The Netherlands – creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading biopharmaceutical companies in each of its core therapeutic fields: fertility, gynecology, anesthesia and neuroscience. Research areas ... include immunology and oncology. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.
Source:
Organon was founded in 1923 and is now a business unit of the Pharma division of Akzo Nobel NV, a multinational company based in The Netherlands. Akzo Nobel produces and markets health care products, coatings, chemicals, and fibers.
Source:
Organon, the human healthcare business unit of Akzo Nobel, has moved Org 50081, a Serotonin 2 blocker (S2B) for the treatment of insomnia, into Phase III clinical development. About 70 million Americans each year suffer from symptoms of insomnia, which can lead to problems with daytime functioning. Insomnia tends to occur more often in elderly and women and is associated with an increased risk for developing other illnesses such as depression. The number of people treated for insomnia is expected to substantially increase over the next several years.
Source:
MORE ABOUT
Akzo Nobel